Skip to main content
Log in

Nouvelles pistes dans le traitement du sepsis — Place des statines

Novel approaches in the treatment of sepsis — The place of statins

  • Enseignement Supérieur en Réanimation
  • Published:
Réanimation

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Références

  1. Kumana CR, Cheung BM, Lauder IJ (2003) Simvastatin reduced mortality and vascular events in high-risk patients. ACP J Club 138(1):2–3

    CAS  PubMed  Google Scholar 

  2. No authors list] (1994) Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344(8934):1383–1389

    Google Scholar 

  3. No authors list] (1998) Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 339(19):1349–1357

    Google Scholar 

  4. No authors list] (2002) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360(9326):7–22

    Google Scholar 

  5. Sever PS, Dahlof B, Poulter NR, et al (2003) Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361(9364):1149–1158

    Article  CAS  PubMed  Google Scholar 

  6. Cannon CP, Braunwald E, McCabe CH, et al (2004) Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350(15):1495–1504

    Article  CAS  PubMed  Google Scholar 

  7. Chan KY, Boucher ES, Gandhi PJ, Silva MA (2004) HMG-CoA reductase inhibitors for lowering elevated levels of C-reactive protein. Am J Health Syst Pharm 61(16):1676–1681

    CAS  PubMed  Google Scholar 

  8. Arnaud C, Mach F (2005) Pleiotropic effects of statins in atherosclerosis: role on endothelial function, inflammation and immunomodulation. Arch Mal Coeur Vaiss 98(6):661–666

    CAS  PubMed  Google Scholar 

  9. Kleemann R, Verschuren L, de Rooij BJ, et al (2004) Evidence for anti-inflammatory activity of statins and PPARalpha activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes in vitro. Blood 103(11):4188–4194

    Article  CAS  PubMed  Google Scholar 

  10. Diomede L, Albani D, Sottocorno M, et al (2001) In vivo antiinflammatory effect of statins is mediated by nonsterol mevalonate products. Arterioscler Thromb Vasc Biol 21(8):1327–1332

    Article  CAS  PubMed  Google Scholar 

  11. Hernandez-Presa MA, Ortego M, Tunon J, et al (2003) Simvastatin reduces NF-kappaB activity in peripheral mon-onuclear and in plaque cells of rabbit atheroma more markedly than lipid lowering diet. Cardiovasc Res 57(1):168–177

    Article  CAS  PubMed  Google Scholar 

  12. Steiner S, Speidl WS, Pleiner J, et al (2005) Simvastatin blunts endotoxin-induced tissue factor in vivo. Circulation 111(14): 1841–1846

    Article  CAS  PubMed  Google Scholar 

  13. Fenton JW, 2nd, Brezniak DV, Ofosu FA, et al (2005) Statins and thrombin. Curr Drug Targets Cardiovasc Haematol Disord 5(2):115–120

    Article  CAS  PubMed  Google Scholar 

  14. Colli S, Eligini S, Lalli M, et al (1997) Vastatins inhibit tissue factor in cultured human macrophages. A novel mechanism of protection against atherothrombosis. Arterioscler Thromb Vasc Biol 17(2):265–272

    CAS  PubMed  Google Scholar 

  15. Ferro D, Basili S, Alessandri C, et al (2000) Inhibition of tissuefactor-mediated thrombin generation by simvastatin. Atherosclerosis 149(1):111–116

    Article  CAS  PubMed  Google Scholar 

  16. Krysiak R, Okopien B, Herman Z (2003) Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes. Drugs 63(17):1821–1854

    Article  CAS  PubMed  Google Scholar 

  17. Shi J, Wang J, Zheng H, et al (2003) Statins increase thrombomodulin expression and function in human endothelial cells by a nitric oxide-dependent mechanism and counteract tumor necrosis factor alpha-induced thrombomodulin downregulation. Blood Coagul Fibrinolysis 14(6):575–585

    Article  CAS  PubMed  Google Scholar 

  18. Weber C, Erl W, Weber KS, Weber PC (1997) HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. J Am Coll Cardiol 30(5):1212–1217

    Article  CAS  PubMed  Google Scholar 

  19. Weitz-Schmidt G, Welzenbach K, Brinkmann V, et al (2001) Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 7(6):687–692

    Article  CAS  PubMed  Google Scholar 

  20. Stefanec T (2000) Endothelial apoptosis: could it have a role in the pathogenesis and treatment of disease? Chest 117(3):841–854

    Article  CAS  PubMed  Google Scholar 

  21. Kureishi Y, Luo Z, Shiojima I, et al (2000) The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 6(9):1004–1010

    Article  CAS  PubMed  Google Scholar 

  22. Landmesser U, Engberding N, Bahlmann FH, et al (2004) Statininduced improvement of endothelial progenitor cell mobilization, myocardial neovascularization, left ventricular function, and survival after experimental myocardial infarction requires endothelial nitric oxide synthase. Circulation 110(14):1933–1939

    Article  CAS  PubMed  Google Scholar 

  23. Pleiner J, Schaller G, Mittermayer F, et al (2004) Simvastatin prevents vascular hyporeactivity during inflammation. Circulation 110(21):3349–3354

    Article  CAS  PubMed  Google Scholar 

  24. Giusti-Paiva A, Martinez MR, Felix JV, et al (2004) Simvastatin decreases nitric oxide overproduction and reverts the impaired vascular responsiveness induced by endotoxic shock in rats. Shock 21(3):271–275

    Article  CAS  PubMed  Google Scholar 

  25. Wagner AH, Schwabe O, Hecker M (2002) Atorvastatin inhibition of cytokine-inducible nitric oxide synthase expression in native endothelial cells in situ. Br J Pharmacol 136(1):143–149

    Article  CAS  PubMed  Google Scholar 

  26. Landry DW, Oliver JA (2001) The pathogenesis of vasodilatory shock. N Engl J Med 345(8):588–595

    Article  CAS  PubMed  Google Scholar 

  27. McGown CC, Brookes ZL (2007) Beneficial effects of statins on the microcirculation during sepsis: the role of nitric oxide. Br J Anaesth 98(2):163–175

    Article  CAS  PubMed  Google Scholar 

  28. Yasuda H, Yuen PS, Hu X, et al (2006) Simvastatin improves sepsis-induced mortality and acute kidney injury via renal vascular effects. Kidney Int 69(9):1535–1542

    Article  CAS  PubMed  Google Scholar 

  29. Merx MW, Liehn EA, Janssens U, et al (2004) HMG-CoA reductase inhibitor simvastatin profoundly improves survival in a murine model of sepsis. Circulation 109(21):2560–2565

    Article  CAS  PubMed  Google Scholar 

  30. Merx MW, Liehn EA, Graf J, et al (2005) Statin treatment after onset of sepsis in a murine model improves survival. Circulation 112(1):117–124

    Article  CAS  PubMed  Google Scholar 

  31. Falagas ME, Makris GC, Matthaiou DK, Rafailidis PI (2008) Statins for infection and sepsis: a systematic review of the clinical evidence. J Antimicrob Chemother 61(4):774–785

    Article  CAS  PubMed  Google Scholar 

  32. Kopterides P, Falagas ME (2009) Statins for sepsis: a critical and updated review. Clin Microbiol Infect 15(4):325–334

    Article  CAS  PubMed  Google Scholar 

  33. Tleyjeh IM, Kashour T, Hakim FA, et al (2009) Statins for the prevention and treatment of infections: a systematic review and meta-analysis. Arch Intern Med 169(18):1658–1667

    Article  PubMed  Google Scholar 

  34. Janda S, Young A, Fitzgerald JM, et al (2010) The effect of statins on mortality from severe infections and sepsis: a systematic review and meta-analysis. J Crit Care [Epub ahead of print]

  35. Majumdar SR, McAlister FA, Eurich DT, et al (2006) Statins and outcomes in patients admitted to hospital with community acquired pneumonia: population based prospective cohort study. BMJ 333(7576):999

    Article  PubMed  Google Scholar 

  36. Mortensen EM, Restrepo MI, Copeland LA, et al (2006) Statins and outcomes in patients with pneumonia: not only healthy user bias. BMJ 333(7578):1123–1124

    Article  PubMed  Google Scholar 

  37. Nipah R (2006) Statins and outcomes in patients with pneumonia: not the best combination. BMJ 333(7578):1124

    Article  PubMed  Google Scholar 

  38. Hak E, Hoes AW (2006) Statins and outcomes in patients with pneumonia: appreciating bias and precision in study. BMJ 333(7578):1124

    Article  PubMed  Google Scholar 

  39. Kruger P, Fitzsimmons K, Cook D, et al (2006) Statin therapy is associated with fewer deaths in patients with bacteraemia. Intensive Care Med 32(1):75–79

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to A. Mekontso Dessap.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mekontso Dessap, A. Nouvelles pistes dans le traitement du sepsis — Place des statines. Réanimation 20 (Suppl 2), 437–440 (2011). https://doi.org/10.1007/s13546-010-0132-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13546-010-0132-z

Navigation